Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.4483
+0.0179 (4.16%)
Aug 11, 2026, 3:37 PM EDT - Market open

Moleculin Biotech Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Income
-27.03-25.1-26.64-29.63-30.64-22.97
Net Income
-42.37-33.66-26.05-29.77-29.03-15.89
Earnings Per Share
-2.21-28.42-189.14-376.75-380.50-221.25
EPS Growth
------

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
10.328.884.2823.5543.1570.9
Total Debt
0.190.220.360.470.340.06
Net Cash (Debt)
10.138.663.9223.0842.8170.84
Net Cash Growth
37.10%120.82%-83.01%-46.10%-39.57%371.83%
Net Cash Per Share
4.787.3128.46292.01561.23988.43

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-24.28-22.74-23.86-23.59-27.64-18.95
Capital Expenditures
---0.01-0.12-0.07-0.02
Free Cash Flow
-24.28-22.74-23.88-23.72-27.71-18.97
Free Cash Flow Growth
------

Valuation

Selected indicators aren't available for this stock.